Rituximab as a front-line therapy for adult-onset minimal change disease with nephrotic syndrome

Minimal change disease (MCD) accounts for 15% of adult nephrotic syndrome (NS) cases. Adult-MCD patients may have more severe clinical features than pediatric patients. In children, Rituximab (RTX) has been used since 2006 to treat frequently relapsing NS. In adults, data about the efficacy of RTX f...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Oncotarget
Huvudupphovsmän: Fenoglio, Roberta, Sciascia, Savino, Beltrame, Giulietta, Mesiano, Paola, Ferro, Michela, Quattrocchio, Giacomo, Menegatti, Elisa, Roccatello, Dario
Materialtyp: Artigo
Språk:Inglês
Publicerad: Impact Journals LLC 2018
Ämnen:
Research Paper: Immunology
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC6034752/
https://ncbi.nlm.nih.gov/pubmed/29989000
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25612
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk